Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan; Department of Pharmacy, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan.
Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad, Pakistan.
Biomed Pharmacother. 2021 Jul;139:111567. doi: 10.1016/j.biopha.2021.111567. Epub 2021 Apr 10.
This study was designed to determine the effectiveness of 5-(3-Hydroxybenzylidene)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione (SR-5), 5-(4-Hydroxybenzylidene)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione (SR-8), 5-(3-Chlorobenzylidene)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione (SR-9) and 5-(4-Chlorobenzylidene)-2, 4, 6(1H, 3H, 5H)-pyrimidinetrione (SR-10) against hypertension. In deoxycorticosterone acetate-salt rats, SR-5, SR-8, SR-9, and SR-10 reduced blood pressure and normalized renal functions. In isolated rat aortic rings, SR-5, SR-8, SR-9, and SR-10 relaxed phenylephrine (PE) and K-induced contractions. The vasodilator effect was endothelium-independent. Test compounds caused a rightward shift of Ca and PE concentration-response curves with a reduction of maximum response. SR-5, SR-8, SR-9, and SR-10 inhibited PE peak contractions in a Ca free medium. In guinea-pig atria, SR5, SR-8, SR-9, and SR-10 caused a mild-to-moderate inhibition of force and rate of contractions. In the aorta and heart tissues, the test compounds enhanced glutathione-s-transferase, reduced glutathione and catalase levels, improved cellular architecture, and decreased lipid peroxidation and expression of inflammatory markers: cyclooxygenase 2, tumor necrosis factor alpha, phosphorylated c-Jun N-terminal kinase, and phosphorylated-nuclear factor kappa B, evidenced in the immunohistochemistry, enzyme-linked immunosorbent assay, western blot molecular investigations and a decreased mRNA expression of calcium channel in RT-PCR analysis. SR-5, SR-8, SR-9, and SR-10 increased the urinary output in rats and inhibited the human platelet aggregation. This study revealed that SR-5, SR-8, SR-9, and SR-10 possess BP lowering, reno-protective, vasodilatory (mediated via Ca antagonist, antioxidant and anti-inflammatory pathways), partial cardio-suppressant, diuretic, and antiplatelet effects, demonstrating their therapeutic potential in hypertension management.
本研究旨在确定 5-(3-羟基苯亚甲基)-2,4,6(1H,3H,5H)-嘧啶三酮(SR-5)、5-(4-羟基苯亚甲基)-2,4,6(1H,3H,5H)-嘧啶三酮(SR-8)、5-(3-氯苯亚甲基)-2,4,6(1H,3H,5H)-嘧啶三酮(SR-9)和 5-(4-氯苯亚甲基)-2,4,6(1H,3H,5H)-嘧啶三酮(SR-10)对高血压的疗效。在去氧皮质酮-醋酸盐盐大鼠中,SR-5、SR-8、SR-9 和 SR-10 降低了血压并使肾功能正常化。在分离的大鼠主动脉环中,SR-5、SR-8、SR-9 和 SR-10 舒张了苯肾上腺素(PE)和 K 诱导的收缩。血管舒张作用是内皮细胞独立的。测试化合物使 Ca 和 PE 浓度-反应曲线向右移位,最大反应减少。SR-5、SR-8、SR-9 和 SR-10 在无 Ca 介质中抑制 PE 峰收缩。在豚鼠心房中,SR5、SR-8、SR-9 和 SR-10 导致力和收缩率的轻度至中度抑制。在主动脉和心脏组织中,测试化合物增强了谷胱甘肽-S-转移酶、还原型谷胱甘肽和过氧化氢酶水平,改善了细胞结构,减少了脂质过氧化和炎症标志物的表达:环加氧酶 2、肿瘤坏死因子-α、磷酸化 c-Jun N-末端激酶和磷酸化核因子 kappa B,在免疫组织化学、酶联免疫吸附试验、western blot 分子研究中得到证实,并在 RT-PCR 分析中降低了钙通道的 mRNA 表达。SR-5、SR-8、SR-9 和 SR-10 增加了大鼠的尿排量并抑制了人血小板聚集。本研究表明,SR-5、SR-8、SR-9 和 SR-10 具有降压、肾保护、血管舒张(通过钙拮抗剂、抗氧化和抗炎途径介导)、部分心脏抑制、利尿和抗血小板作用,证明了它们在高血压管理中的治疗潜力。